Merged INC Research, InVentiv rebrand as Syneos

With their $7.4 billion merger complete, Raleigh-based INC Research and InVentiv have rebranded as Syneos Health Inc.

The Contract Research Organization (CRO) and Contract Commercial Organization (CCO) formed by the merger trades on Nasdaq under the symbol SYNH.

The company explained that “The word Syneos (pronounced SIN-ee-ohs) communicates the value of synchronizing clinical and commercial capabilities to accelerate customer performance. Syneos Health solutions are fully integrated - sharing knowledge, data and insights - to deliver better processes and smarter practices to speed the delivery of biopharmaceutical therapies to market.”

It adds, “The name is also derived from ‘neo,’ signaling a new approach to problem-solving and a new biopharmaceutical solutions category for the healthcare workforce.”

Allstair Macdonald, CEO, said the rebranding reflects the qualities of the merged company.

“Syneos Health fully expresses our value proposition -- that is, our ability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialize their therapies," he said when the rebranding was announced.

Macdonald continued, "As commercialization experts, we understand the importance a strong brand plays in creating differentiation, conversion and loyalty. Our new identity reinforces our fully integrated business model, positions Syneos Health as a high-value solutions partner, and is designed to attract and retain top talent committed to shortening the distance from lab to life.”

Syneos Health tapped its own industry-leading branding agency, Addison Whitney, to create the company's new identity. Addison Whitney creates brand identities for corporations, employer brands, consumer brands and biopharmaceutical therapies, including half of the top 200 medicines approved and launched in the last 10 years.

The company employs 21,000 people.